nature portfolio

Corresponding author(s):	Yong Yu
Last updated by author(s):	Sep 28, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

\sim				
⟨.	tっ	÷ι	ct	ICS
٠,	_		^ 1	11 >

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed					
	The exact	e exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A stateme	tatement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statist	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
\boxtimes	A descript	A description of all covariates tested				
\boxtimes	A descript	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full desc AND varia	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>					
\boxtimes	For Bayesi	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
\boxtimes	\boxtimes Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software and code						
Poli	cy information a	about <u>availability of computer code</u>				
Da	nta collection	pClamp 10 (Molecular Devices) was used for electrophysiology recording				
		Clampfit 10 (Molecular Devices) was used for electrophysiology data analysis, Prism 8 (GraphPad) was used for data plotting, and PyMol-2 3.2 was used for structural figure preparation.				

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Relevant data are available upon reasonable request.

Human rese	arch parti	cipants		
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.		
Reporting on sex	and gender	N/A		
Population chara	cteristics	N/A		
Recruitment		N/A		
Ethics oversight N/A		N/A		
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.		
Field-spe	ecific re	porting		
Please select the o	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences	□В	ehavioural & social sciences		
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces stu	udy design		
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size	based on our p	ectrophysiology recording, more than 5 oocytes (in most of cases more than 8) were tested for each mutants. The number is selected our previous experience and what people generally do in electrophysiology filed. This size is sufficient for performing the statistical ple size was not applied to the structural analysis.		
Data exclusions	Electrophysiolo	gy recording data from a small number of oocytes that have big leak currents (due to bad oocyte quality) were excluded.		
Replication		rding data have been successfully repeated with at least two to three batches of oocytes and all results were similar. Western blot was leated successfully.		
Randomization	Xenopus oocyt	nopus oocytes were randomly selected for injection and current recording.		
Blinding	Blinding was not performed in electrophysiology recording since the protocol was straightforward and was performed identically to the WT and mutants by computer controlled equipment. Data analysis was also performed by computer based method.			
		Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,		
system or method lis	ted is relevant to	your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & ex	perimental s	ystems Methods		
n/a Involved in th		n/a Involved in the study		
Eukaryotic				
Palaeontology and archaeology MRI-based neuroimaging				

Antibodies

Antibodies used

Animals and other organisms

Dual use research of concern

Clinical data

Primary antibodies: mouse monoclonal anti-ß-actin (GenScript A00702-200), rabbit monoclonal anti-HA (Cell Signaling, 3724S). Secondary antibodies: IRDye® 680RD goat anti-mouse (LI-COR Biosciences, 926-68070) and IRDye® 800CW goat anti-rabbit IgG (LI-COR Biosciences,, 926-32211).

Validation

All antibodies are validated with negative control samples in our lab. The mouse anti-ß-actin antibody from GenScript and the rabbit monoclonal anti-HA antibody from Cell Signaling have been widely used in literature including previous publication from us.

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals

Oocytes from female Xenopus Laevis frog were used for expressing our ion channel and conducting electrophysiology recording.

Wild animals

The study did not involve wild animals.

N/A. Only oocytes were used.

Field-collected samples

The study did not involve samples collected from field.

Ethics oversight Institutional Animal Care and Use Committee (IACUC) at St. John's University has approved the frog use protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.